Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

  title={Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison},
  author={Christopher P. Cannon and Sean P. Curtis and Garret A. FitzGerald and Henry Krum and Amarjot Kaur and James A. Bolognese and Alise S. Reicin and Claire Bombardier and Michael E. Weinblatt and D{\'e}sir{\'e}e van der Heijde and Erland Erdmann and Loren Laine},
  journal={The Lancet},

Figures and Tables from this paper

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)

Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg, and resulted in similar efficacy in patients with rheumatoid arthritis.

Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis

The benefit-risk profile of diclofenac was comparable to other treatments used for pain relief in OA and RA; benefits and risks vary in individuals and need consideration when making treatment decisions.

Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.

The drug was associated with fewer uncomplicated upper gastrointestinal adverse events than nonselective NSAIDs, and was noninferior to diclofenac in terms of the rate of thrombotic cardiovascular events.

Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).

Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac, but a greater risk of renovascular AEs but a more favourable GI/liver tolerability profile.

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo

Etoricoxib was comparable to placebo, celecoxib, and ibuprofen for effects on the CV risk markers measured, and was not different from Placebo, cele Coxib, or ibup rofen for any biomarker.

Efficacy and safety of etoricoxib in the treatment of osteoarthritis

  • A. Sebba
  • Medicine
    Expert review of clinical pharmacology
  • 2008
Large-scale studies addressing the efficacy, GI tolerability and potential for CV events with etoricoxib have now been published, and several patient types appear to benefit, including those with CV risk factors and those requiring gastroprotective agents.

Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs

It appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound.

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

Treatment with etoricoxib 90 mg was associated with significantly better GI tolerability compared to diclofenac in this population of patients with OA, and resulted in similar improvements in PGADS from baseline.

Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials

The increased cardiovascular risks associated with diclofenac initiation were higher than for other older COX-2 inhibitors (meloxicam/etodolac) and comparable to coxibs (celecoxib/etoricoxib).



Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.

Single daily doses of valdecoxib 20 and 40 mg provided efficacy comparable to that of diclofenac, with a superior upper GI safety profile in the long-term treatment of RA patients.

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

The data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks and was generally well tolerated in patients withRA.

Efficacy and Tolerability Profile of Etoricoxib in Patients with Osteoarthritis: A Randomized, Double-blind, Placebo and Active-comparator Controlled 12-Week Efficacy Trial

Etoricoxib showed rapid and durable treatment effects in patients with OA of the knee or hip and was generally well tolerated.

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.

Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population

The results do not support the existence of a clinically meaningful interaction between aspirin and NSAIDs, including ibuprofen, including aspirin taken concomitantly.